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The outbreak of mosquito-borne yellow fever virus (YFV) in Angola 2016 rapidly spread to urban regions and 
other countries. Vaccination campaigns were subsequently intensified, but the increased vaccine demand led to 
depleted stockpiles. Current yellow fever vaccine manufacturing processes rely on embryonated chicken eggs, 
which are strongly limited with respect to flexible capacity increase in emergencies. The global vaccine demand 
is estimated by the WHO to 1.38 billion doses needed to eliminate epidemics. Thus, an urgent need for an 
improved production platform is needed, ideally transferable to new vaccine developments against emerging 
flaviviruses, such as Zika virus. 
 
Here we present a cell culture-based YFV 17D and Zika virus (ZIKV) production process using the EB66® cell 
line. The avian EB66® suspension cell line grew fast and stable in chemically defined medium to cell 
concentrations of 1.8 × 107 cells/mL in shake flasks and batch mode. Seed virus was prepared from Vero-
derived YFV and ZIKV material over five passages in EB66® cells. Thereby, infectious virus titers successfully 
increased by one log unit and maximum titers of 1.4×108 PFU/mL (infectious virions per mL) and 
8.0×107 PFU/mL were obtained two days post infection for YFV and ZIKV, respectively.  
The process was intensified using perfusion bioreactors to increase cell concentrations. Therefore, EB66® cells 
were cultivated in 1 L benchtop bioreactors equipped with an alternating tangential flow filtration (ATF2) 
perfusion unit. Perfusion rates were adjusted to maintain glutamine concentrations above 1 mM and cells grew 
up to 9.5×107 cells/mL. A maximum YFV titer of 7.3 × 108 PFU/mL was achieved. The cell-specific virus yield 
(CSVY) was 8 PFU/cell, similar to shake flask experiments. 
 
For ZIKV production, another approach aimed at the use of on-line capacitance sensors to control cell-specific 
perfusion rates (CSPRs) based on cell concentrations. This automated system was set to a CSPR of 0.017 and 
0.034 nL/cell/day leading to maximum cell concentrations of 8.9×107 cells/mL and 1.6×108 cells/mL. ZIKV titers 
peaked after three to four days post infection with 2.6×109 PFU/mL and 1.0×1010 PFU/mL, respectively. CSVYs 
increased from 5 PFU/cell (shake flask experiments) to 30 PFU/cell and even above 64 PFU/cell in this set-up. 
The increased CSPR resulted in an improved volumetric productivity by factor three compared to the lower 
CSPR. 
 
Further process intensification was achieved by direct cell inoculation to the ZIKV production bioreactor. A 
15 mL cryo-bag was thawed with 8.5×108 cells and cell viabilities of 90% after inoculation quickly increased over 
the cultivation period. 
 
Taken together, EB66® suspension cells can be grown to concentrations exceeding 1.5×108 cells/mL in 
perfusion bioreactors, and cells are highly permissive for YFV and ZIKV. YFV production using perfusion 
systems generated virus material equivalent to 10 Mio vaccine doses (4.7 log infectious units per dose) in less 
than two weeks operation time. With the use of on-line sensors to adjust CSPRs meeting cellular nutrient 
demands, ZIKV titers exceeding 1.0×1010 PFU/mL were obtained for the first time. Direct cryo-bag inoculation 
shortened the seed train phase, and virus production was initiated with full flexibility. This is a powerful 
demonstration on how next generation flavivirus vaccine production can be realized. 
 
